Evidence map›Paper›PMID 33024996›Full record

ArticleBlood2021

Conditional expression of HGAL leads to the development of diffuse large B-cell lymphoma in mice.

Javier Raboso-Gallego, Ana Casado-García, Xiaoyu Jiang, Marta Isidro-Hernández, Andrew J Gentles, Shuchun Zhao, Yaso Natkunam, Oscar Blanco, Verónica Domínguez, Belén Pintado and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Blood, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Oncogenes, Proto-Oncogenes, and Lineage Restriction of Cancer Stem Cells.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 3 countries.

Javier Raboso-GallegoExperimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, Centro Superior de Investigaciones Científicas (CSIC)/Universidad de Salamanca (USAL), Salamanca, Spain.
Ana Casado-GarcíaExperimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, Centro Superior de Investigaciones Científicas (CSIC)/Universidad de Salamanca (USAL), Salamanca, Spain.
Xiaoyu JiangDivision of Hematology, Department of Medicine, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL.
Marta Isidro-HernándezExperimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, Centro Superior de Investigaciones Científicas (CSIC)/Universidad de Salamanca (USAL), Salamanca, Spain.
Andrew J GentlesDepartment of Medicine.
Shuchun ZhaoDepartment of Pathology, Stanford University School of Medicine, Stanford, CA.
Yaso NatkunamDepartment of Pathology, Stanford University School of Medicine, Stanford, CA.
Oscar BlancoInstitute for Biomedical Research of Salamanca, Salamanca, Spain.
Verónica DomínguezTransgenesis Facility Centro Nacional de Biotecnología-Centro de Biología Molecular Severo Ochoa (CNB-CBMSO), Consejo Superior de Investigaciones Cientificas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain.
Belén PintadoTransgenesis Facility Centro Nacional de Biotecnología-Centro de Biología Molecular Severo Ochoa (CNB-CBMSO), Consejo Superior de Investigaciones Cientificas-Universidad Autónoma de Madrid (CSIC-UAM), Madrid, Spain.
Diego Alonso-LópezBioinformatics Unit and.
Javier De Las RivasInstitute for Biomedical Research of Salamanca, Salamanca, Spain.
Carolina Vicente-DueñasInstitute for Biomedical Research of Salamanca, Salamanca, Spain.
Izidore S LossosDivision of Hematology, Department of Medicine, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL.
Isidro Sanchez-GarciaExperimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, Centro Superior de Investigaciones Científicas (CSIC)/Universidad de Salamanca (USAL), Salamanca, Spain.
Universidad de Salamanca · ESConsejo Superior de Investigaciones Científicas · ESInstituto de Investigación Biomédica de Salamanca · ESStanford University · USUniversity of Miami · USBioinformatics Institute · SG

Funding

Identify the Mechanisms of LMO2-Mediated Inhibition of Homologous Recombination and Establish PARP-Targeted Synthetic Lethality as a New Therapy for DLBCLR01CA233945 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LOSSOS, IZIDORE S, VERDUN, RAMIRO ERNESTO · 2019 to 2023
$1.8M
NCI NIH HHS R01 CA233945
6 · The paper itself

Abstract

Diffuse large B-cell lymphomas (DLBCLs) are clinically and genetically heterogeneous tumors. Deregulation of diverse biological processes specific to B cells, such as B-cell receptor (BCR) signaling and motility regulation, contribute to lymphomagenesis. Human germinal center associated lymphoma (HGAL) is a B-cell-specific adaptor protein controlling BCR signaling and B lymphocyte motility. In normal B cells, it is expressed in germinal center (GC) B lymphocytes and promptly downregulated upon further differentiation. The majority of DLBCL tumors, primarily GC B-cell types, but also activated types, express HGAL. To investigate the consequences of constitutive expression of HGAL in vivo, we generated mice that conditionally express human HGAL at different stages of hematopoietic development using 3 restricted Cre-mediated approaches to initiate expression of HGAL in hematopoietic stem cells, pro-B cells, or GC B cells. Following immune stimulation, we observed larger GCs in mice in which HGAL expression was initiated in GC B cells. All 3 mouse strains developed DLBCL at a frequency of 12% to 30% starting at age 13 months, leading to shorter survival. Immunohistochemical studies showed that all analyzed tumors were of the GC B-cell type. Exon sequencing revealed mutations reported in human DLBCL. Our data demonstrate that constitutive enforced expression of HGAL leads to DLBCL development.

Indexed as

AnimalsCarcinogenesisCell LineFemaleGain of Function MutationGene Expression Regulation, NeoplasticGerminal CenterHematopoietic Stem CellsHumansIntracellular Signaling Peptides and ProteinsLymphoma, Large B-Cell, DiffuseMiceMice, Inbred C57BLMicrofilament ProteinsGCSAM protein, humanIntracellular Signaling Peptides and ProteinsMicrofilament Proteins

Identifiers

PMID33024996
PMCPMC8020264
OpenAlexW3091899966

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.